- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06588504
Étude de recherche au Japon pour comparer le Dasiglucagon au Glucagon dans le traitement de très faibles niveaux de sucre dans le sang chez les adultes asiatiques atteints de diabète de type 1 et tester le Dasiglucagon pour la même maladie chez les adolescents japonais
Une étude de phase 3, randomisée, ouverte et croisée pour confirmer l'efficacité clinique et l'innocuité du dasiglucagon par rapport au glucagon pour le traitement de l'hypoglycémie sévère chez les adultes asiatiques atteints de diabète de type 1 (DT1), y compris une étude sur le dasiglucagon chez un adolescent japonais Cohorte
This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low blood sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D. This study wants to demonstrate that dasiglucagon can raise low blood sugar levels just as well as glucagon. Participants will get dasiglucagon and glucagon. In which treatment order participants get study medicines (dasiglucagon and glucagon) is decided by chance. Dasiglucagon is a new medicine, but doctors can prescribe it in the US as it is approved there. Doctors can prescribe glucagon in multiple countries including Japan as an approved medicine. The study will last for about 17 weeks. Participant cannot be in the study if the study doctor thinks that there are risks for participants health. Women cannot take part if pregnant, breast-feeding, plan to get pregnant, during the study period, or not using adequate contraceptive methods. For man: if participant have sex, participant and his partner must use an adequate birth control method during the study.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Fukuoka, Japon, 812-0025
- Hakata Clinic
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- For Adults: Asian male or female; For Adolescents: Japanese male or female.
- Age at the time of signing the informed consent:
For Adults: Age 18-75 years (both inclusive):
For Adolescents: Age 12-15 years (both inclusive).
- Diagnosed with T1D greater than (>)1 year before screening.
- Glycated haemoglobin (HbA1c) less than (<)10.0 percentage (%) (86 millimoles per mole [mmol/mol]) as assessed by subcontracted laboratory by the site on the day of screening.
- For adults: BMI between 18.5 and 29.9 kilogram per meter square (kg/m2) (both inclusive).
For adolescents: Body weight greater than or equal to (≥) 33.4 kilograms (kg).
- Treated with stable insulin treatment (based on the investigator's discretion preferably no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening.
- For Japanese participants: Japanese passport or equivalent For non-Japanese participants: Asian (non- Japanese passport or equivalent).
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention(s) or related products (glucagon or its derivatives).
- Exposure to an investigational medicinal product (IMP) within 30 days or 5 times the half-life of the IMP (if known), whichever is longest before screening.
- Severe hypoglycaemia in the last month prior to screening.
- Hospitalisation for diabetic ketoacidosis (DKA) in the last month prior to screening.
- Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus).
- History of epilepsy or seizure disorder.
- Known presence or history of pheochromocytoma (i.e., adrenal gland tumour) or insulinoma (i.e., insulin-secreting pancreas tumour).
- Clinically significant abnormal electrocardiogram (ECG) at screening as evaluated by investigator.
- Any disorder, unwillingness or inability which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol.
As declared by the participant or in the medical records.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Adult Cohort: Dasiglucagon then Glucagon
Participants will receive a single subcutaneous (s.c.) injection of dasiglucagon in first dosing visit then a single intra-mascular (i.m.) injection of glucagon in next dosing visit. |
Participants will receive s.c. injection of dasiglucagon. |
|
Expérimental: Adult Cohort: Glucagon then Dasiglucagon
Participants will receive a single i.m. injection of glucagon in first dosing visit then a single s.c. injection of dasiglucagon in next dosing visit. |
Participants will receive s.c. injection of dasiglucagon. Participants will receive i.m. injection of glucagon. |
|
Expérimental: Adolescent Cohort: Dasiglucagon
Participants will receive a single s.c. injection of dasiglucagon. |
Participants will receive s.c. injection of dasiglucagon. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to Plasma Glucose (PG) Recovery in Adults: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline
Délai: Baseline (Day 1), Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 90 minutes after IMP injection
|
This outcome measure reported time to PG recovery in Asian Japanese adults. PG recovery was defined as the first increase in PG of greater than or equal to (≥) 20 milligrams per deciliter (mg/dL) (1.1 millimoles per liter [mmol/L]) from baseline. Time to PG recovery was derived using linear interpolation between the last observed time point before recovery and the first observed time point after recovery, based on actual sampling time points with time zero as time of IMP injection. |
Baseline (Day 1), Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 90 minutes after IMP injection
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to Plasma Glucose Recovery in Adolescents: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline (Japanese Adolescent Cohort Only)
Délai: Baseline (Day 1), Visit 2-Day 1 (Day 1): 0 to 90 minutes after IMP injection
|
This outcome measure reported time to PG recovery in adolescents Japanese population. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline. Time to PG recovery was derived using linear interpolation between the last observed time point before recovery and the first observed time point after recovery, based on actual sampling time points with time zero as time of IMP injection. |
Baseline (Day 1), Visit 2-Day 1 (Day 1): 0 to 90 minutes after IMP injection
|
|
Number of Participants Achieving PG Recovery Within 30 Minutes After IMP Injection (Yes/No)
Délai: Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 30 minutes after IMP injection
|
This outcome measure reported number of participants achieving PG recovery within 30 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline. |
Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 30 minutes after IMP injection
|
|
Number of Participants Achieving PG Recovery Within 20 Minutes After IMP Injection (Yes/No)
Délai: Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 20 minutes after IMP injection
|
This outcome measure reported number of participants achieving PG recovery within 20 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline. |
Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 20 minutes after IMP injection
|
|
Number of Participants Achieving PG Recovery Within 15 Minutes After IMP Injection (Yes/No)
Délai: Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 15 minutes after IMP injection
|
This outcome measure reported number of participants achieving PG recovery within 15 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline. |
Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 15 minutes after IMP injection
|
|
Change From Baseline in Plasma Glucose at 15 Minutes After IMP Injection
Délai: Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 15 minutes after IMP injection
|
This outcome measure reports change from baseline in plasma glucose at 15 minutes after IMP injection for all participants in adults and adolescents arms. |
Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 15 minutes after IMP injection
|
|
Change From Baseline in Plasma Glucose at 20 Minutes After IMP Injection
Délai: Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 20 minutes after IMP injection
|
This outcome measure reports change from baseline in plasma glucose at 20 minutes after IMP injection for all participants in adults and adolescents arms. |
Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 20 minutes after IMP injection
|
|
AUC0-30min: Area Under the Plasma Dasiglucagon Concentration Time Curve From 0 to 30 Minutes After IMP Injection
Délai: Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, and 30 minutes (From 0 to 30 minutes after IMP injection)
|
This outcome measure reported area under the plasma dasiglucagon concentration (AUC) time curve using the linear trapezoidal technique based on observed values and actual measurement times from 0 to 30 minutes (AUC0-30min) after IMP injection was administered in adult and adolescent participants in each reported arms. |
Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, and 30 minutes (From 0 to 30 minutes after IMP injection)
|
|
Cmax: Maximum Observed Plasma Dasiglucagon Concentration
Délai: Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 210, 300 minutes (From 0 to 5 hours after IMP injection)
|
This outcome measure reported maximum observed plasma dasiglucagon concentration (Cmax) after IMP injection was administered in adult and adolescent participants in each reported dasiglucagon arms. |
Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 210, 300 minutes (From 0 to 5 hours after IMP injection)
|
|
Number of Adverse Events (AEs) for All Participants in Each Arms
Délai: From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 28 days after IMP injection
|
This outcome measure reported Number of adverse events (AEs) for all participants in adults and adolescents arms. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an IMP. |
From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 28 days after IMP injection
|
|
Number of Hypoglycaemic Episodes for All Participants in Each Arms
Délai: From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 12 hours after IMP injection.
|
This outcome measure reports number of hypoglycaemic episodes for all participants in adults and adolescents arms. Hypoglycaemic episode is measured in terms of PG (blood or urine ketones were measured). Hypoglycaemia is defined as a decline in PG to below 70 mg/dL (3.9 mmol/L). Classification of hypoglycaemia (Level; Glycaemic criteria; Description) are as follows: 1) - Hypoglycaemia alert value (level 1); <3.9 mmol/L (70 mg/dL) and ≥3.0 mmol/L (54 mg/dL); Sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy. 2) Clinically significant hypoglycaemia; < 3.0 mmol/L (54 mg/dL); Sufficiently low to indicate serious, clinically important hypoglycaemia (level 2). 3) Severe hypoglycaemia (level 3); No specific glucose threshold; Hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery. |
From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 12 hours after IMP injection.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Maladies métaboliques
- Maladies auto-immunes
- Maladies du système immunitaire
- Troubles du métabolisme du glucose
- Diabète sucré
- Maladies nutritionnelles et métaboliques
- Diabète sucré, type 1
- Hormones
- Hormones, substituts hormonaux et antagonistes hormonaux
- Hormones peptidiques
- Peptides
- Acides aminés, peptides et protéines
- Hormones pancréatiques
- Progcagon
- Glucagon
- dasiglucagon
Autres numéros d'identification d'étude
- NN9515-7675
- U1111-1300-1855 (Autre identifiant: World Health Organization (WHO))
- jRCT2071240050 (Identificateur de registre: Japan Registry for Clinical Trials (jRCT))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .